Clinical-stage cancer biotech Actuate latest to eye summer IPO

Could the IPO window really be reopening for the summer? The second biotech proposition in May seems to suggest the public markets are regaining their allure.

This time, it's Actuate Therapeutics, which has a glycogen synthase kinase‐3 beta (GSK-3β) drug called elraglusib in a phase 2 trial for pancreatic cancer.